Role of thromboxane A2 in the cardiovascular response to intracoronary C5a

G. L. Stahl, Ezra A Amsterdam, J. D. Symons, J. C. Longhurst

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Intracoronary administration of complement component C5a induces transient decreases in coronary blood flow and regional left ventricular segment shortening, associated with intramyocardial granulocyte trapping. We evaluated the influence of a cyclooxygenase inhibitor (acetylsalicylic acid, n = 8) or a thromboxane A2/prostaglandin H2 receptor antagonist (SQ29548, n = 6) on these C5a-induced cardiovascular responses. Open-chest anesthetized pigs were instrumented to monitor heart rate, arterial blood pressure, left anterior descending coronary blood flow, regional left ventricular segment shortening, and dP/dt. Oxygen content, lactate concentration, leukocyte count, and thromboxane B2, the stable metabolite of thromboxane A2, were measured in arterial and regional coronary venous blood. Repetitive injections of intracoronary C5a (500 ng) given 60 minutes apart showed no tachyphylaxis of the hemodynamic response. However, tachyphylaxis was seen in coronary blood flow changes when injections were spaced 30 minutes apart. An increase in myocardial oxygen extraction and lactate production was observed after intracoronary C5a. Administration of acetylsalicylic acid (50 mg/kg i.v.) attenuated C5a-induced decreases in coronary blood flow (-8 ± 1 vs. -3 ± 1 ml/min) and regional left ventricular segmental shortening (-10 ± 3% vs. -2 ± 1%) and blocked the maximal increase in coronary venous thromboxane B2 (2.0 ± 0.1 vs. 0.2 ± 0.1 pmol/ml plasma). Furthermore, SQ29548 (30 μg/kg/min) reduced C5a-induced changes in coronary blood flow (-13 ± 2 vs. -4 ± 2 ml/min) and segmental shortening (-14 ± 2% vs. -3 ± 1%). Neither cyclooxygenase inhibition nor thromboxane A2/prostaglandin H2 antagonism blocked the decrease in coronary venous granulocyte count. Thus, the deleterious cardiac effects of C5a, which include induction of myocardial ischemia, are dependent on the actions of thromboxane A2 in the pig. Our data also suggest that leukocyte extraction alone in the coronary circulation is not sufficient for the myocardial response to anaphylatoxin administration.

Original languageEnglish (US)
Pages (from-to)1103-1111
Number of pages9
JournalCirculation Research
Volume66
Issue number4
StatePublished - 1990

Fingerprint

Thromboxane A2
Tachyphylaxis
Thromboxane B2
Regional Blood Flow
Granulocytes
Aspirin
Lactic Acid
Swine
Complement C5a
Anaphylatoxins
Prostaglandin H2 Receptors Thromboxane A2
Prostaglandin H2
Oxygen
Coronary Circulation
Injections
Cyclooxygenase Inhibitors
Prostaglandin-Endoperoxide Synthases
Leukocyte Count
Myocardial Ischemia
Arterial Pressure

Keywords

  • anaphylatoxin
  • aspirin
  • complement
  • coronary blood flow
  • myocardial ischemia
  • SQ29548

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Stahl, G. L., Amsterdam, E. A., Symons, J. D., & Longhurst, J. C. (1990). Role of thromboxane A2 in the cardiovascular response to intracoronary C5a. Circulation Research, 66(4), 1103-1111.

Role of thromboxane A2 in the cardiovascular response to intracoronary C5a. / Stahl, G. L.; Amsterdam, Ezra A; Symons, J. D.; Longhurst, J. C.

In: Circulation Research, Vol. 66, No. 4, 1990, p. 1103-1111.

Research output: Contribution to journalArticle

Stahl, GL, Amsterdam, EA, Symons, JD & Longhurst, JC 1990, 'Role of thromboxane A2 in the cardiovascular response to intracoronary C5a', Circulation Research, vol. 66, no. 4, pp. 1103-1111.
Stahl, G. L. ; Amsterdam, Ezra A ; Symons, J. D. ; Longhurst, J. C. / Role of thromboxane A2 in the cardiovascular response to intracoronary C5a. In: Circulation Research. 1990 ; Vol. 66, No. 4. pp. 1103-1111.
@article{9e1fde40270048308cb3a23a50222803,
title = "Role of thromboxane A2 in the cardiovascular response to intracoronary C5a",
abstract = "Intracoronary administration of complement component C5a induces transient decreases in coronary blood flow and regional left ventricular segment shortening, associated with intramyocardial granulocyte trapping. We evaluated the influence of a cyclooxygenase inhibitor (acetylsalicylic acid, n = 8) or a thromboxane A2/prostaglandin H2 receptor antagonist (SQ29548, n = 6) on these C5a-induced cardiovascular responses. Open-chest anesthetized pigs were instrumented to monitor heart rate, arterial blood pressure, left anterior descending coronary blood flow, regional left ventricular segment shortening, and dP/dt. Oxygen content, lactate concentration, leukocyte count, and thromboxane B2, the stable metabolite of thromboxane A2, were measured in arterial and regional coronary venous blood. Repetitive injections of intracoronary C5a (500 ng) given 60 minutes apart showed no tachyphylaxis of the hemodynamic response. However, tachyphylaxis was seen in coronary blood flow changes when injections were spaced 30 minutes apart. An increase in myocardial oxygen extraction and lactate production was observed after intracoronary C5a. Administration of acetylsalicylic acid (50 mg/kg i.v.) attenuated C5a-induced decreases in coronary blood flow (-8 ± 1 vs. -3 ± 1 ml/min) and regional left ventricular segmental shortening (-10 ± 3{\%} vs. -2 ± 1{\%}) and blocked the maximal increase in coronary venous thromboxane B2 (2.0 ± 0.1 vs. 0.2 ± 0.1 pmol/ml plasma). Furthermore, SQ29548 (30 μg/kg/min) reduced C5a-induced changes in coronary blood flow (-13 ± 2 vs. -4 ± 2 ml/min) and segmental shortening (-14 ± 2{\%} vs. -3 ± 1{\%}). Neither cyclooxygenase inhibition nor thromboxane A2/prostaglandin H2 antagonism blocked the decrease in coronary venous granulocyte count. Thus, the deleterious cardiac effects of C5a, which include induction of myocardial ischemia, are dependent on the actions of thromboxane A2 in the pig. Our data also suggest that leukocyte extraction alone in the coronary circulation is not sufficient for the myocardial response to anaphylatoxin administration.",
keywords = "anaphylatoxin, aspirin, complement, coronary blood flow, myocardial ischemia, SQ29548",
author = "Stahl, {G. L.} and Amsterdam, {Ezra A} and Symons, {J. D.} and Longhurst, {J. C.}",
year = "1990",
language = "English (US)",
volume = "66",
pages = "1103--1111",
journal = "Circulation Research",
issn = "0009-7330",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Role of thromboxane A2 in the cardiovascular response to intracoronary C5a

AU - Stahl, G. L.

AU - Amsterdam, Ezra A

AU - Symons, J. D.

AU - Longhurst, J. C.

PY - 1990

Y1 - 1990

N2 - Intracoronary administration of complement component C5a induces transient decreases in coronary blood flow and regional left ventricular segment shortening, associated with intramyocardial granulocyte trapping. We evaluated the influence of a cyclooxygenase inhibitor (acetylsalicylic acid, n = 8) or a thromboxane A2/prostaglandin H2 receptor antagonist (SQ29548, n = 6) on these C5a-induced cardiovascular responses. Open-chest anesthetized pigs were instrumented to monitor heart rate, arterial blood pressure, left anterior descending coronary blood flow, regional left ventricular segment shortening, and dP/dt. Oxygen content, lactate concentration, leukocyte count, and thromboxane B2, the stable metabolite of thromboxane A2, were measured in arterial and regional coronary venous blood. Repetitive injections of intracoronary C5a (500 ng) given 60 minutes apart showed no tachyphylaxis of the hemodynamic response. However, tachyphylaxis was seen in coronary blood flow changes when injections were spaced 30 minutes apart. An increase in myocardial oxygen extraction and lactate production was observed after intracoronary C5a. Administration of acetylsalicylic acid (50 mg/kg i.v.) attenuated C5a-induced decreases in coronary blood flow (-8 ± 1 vs. -3 ± 1 ml/min) and regional left ventricular segmental shortening (-10 ± 3% vs. -2 ± 1%) and blocked the maximal increase in coronary venous thromboxane B2 (2.0 ± 0.1 vs. 0.2 ± 0.1 pmol/ml plasma). Furthermore, SQ29548 (30 μg/kg/min) reduced C5a-induced changes in coronary blood flow (-13 ± 2 vs. -4 ± 2 ml/min) and segmental shortening (-14 ± 2% vs. -3 ± 1%). Neither cyclooxygenase inhibition nor thromboxane A2/prostaglandin H2 antagonism blocked the decrease in coronary venous granulocyte count. Thus, the deleterious cardiac effects of C5a, which include induction of myocardial ischemia, are dependent on the actions of thromboxane A2 in the pig. Our data also suggest that leukocyte extraction alone in the coronary circulation is not sufficient for the myocardial response to anaphylatoxin administration.

AB - Intracoronary administration of complement component C5a induces transient decreases in coronary blood flow and regional left ventricular segment shortening, associated with intramyocardial granulocyte trapping. We evaluated the influence of a cyclooxygenase inhibitor (acetylsalicylic acid, n = 8) or a thromboxane A2/prostaglandin H2 receptor antagonist (SQ29548, n = 6) on these C5a-induced cardiovascular responses. Open-chest anesthetized pigs were instrumented to monitor heart rate, arterial blood pressure, left anterior descending coronary blood flow, regional left ventricular segment shortening, and dP/dt. Oxygen content, lactate concentration, leukocyte count, and thromboxane B2, the stable metabolite of thromboxane A2, were measured in arterial and regional coronary venous blood. Repetitive injections of intracoronary C5a (500 ng) given 60 minutes apart showed no tachyphylaxis of the hemodynamic response. However, tachyphylaxis was seen in coronary blood flow changes when injections were spaced 30 minutes apart. An increase in myocardial oxygen extraction and lactate production was observed after intracoronary C5a. Administration of acetylsalicylic acid (50 mg/kg i.v.) attenuated C5a-induced decreases in coronary blood flow (-8 ± 1 vs. -3 ± 1 ml/min) and regional left ventricular segmental shortening (-10 ± 3% vs. -2 ± 1%) and blocked the maximal increase in coronary venous thromboxane B2 (2.0 ± 0.1 vs. 0.2 ± 0.1 pmol/ml plasma). Furthermore, SQ29548 (30 μg/kg/min) reduced C5a-induced changes in coronary blood flow (-13 ± 2 vs. -4 ± 2 ml/min) and segmental shortening (-14 ± 2% vs. -3 ± 1%). Neither cyclooxygenase inhibition nor thromboxane A2/prostaglandin H2 antagonism blocked the decrease in coronary venous granulocyte count. Thus, the deleterious cardiac effects of C5a, which include induction of myocardial ischemia, are dependent on the actions of thromboxane A2 in the pig. Our data also suggest that leukocyte extraction alone in the coronary circulation is not sufficient for the myocardial response to anaphylatoxin administration.

KW - anaphylatoxin

KW - aspirin

KW - complement

KW - coronary blood flow

KW - myocardial ischemia

KW - SQ29548

UR - http://www.scopus.com/inward/record.url?scp=0025194981&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025194981&partnerID=8YFLogxK

M3 - Article

C2 - 2107984

AN - SCOPUS:0025194981

VL - 66

SP - 1103

EP - 1111

JO - Circulation Research

JF - Circulation Research

SN - 0009-7330

IS - 4

ER -